The Cannabist Company Bankruptcy: What Happened and What It Means

Executive Summary

The Cannabist Company, one of the largest multi-state cannabis operators in the United States, filed for Chapter 11 bankruptcy protection on May 18, 2026, marking the most significant financial collapse in the cannabis industry's modern history. The filing affects operations across 19 states and approximately 130 retail dispensaries, cultivation facilities, and processing centers. The bankruptcy represents the culmination of years of mounting debt, federal banking restrictions, punitive taxation under Internal Revenue Code Section 280E, and deteriorating wholesale cannabis prices that compressed margins across the industry. The Cannabist Company's collapse sends shockwaves through the cannabis sector, raising urgent questions about the viability of large-scale multi-state operators under current federal prohibition and highlighting the structural disadvantages that prevent cannabis businesses from accessing traditional bankruptcy protections under Chapter 11 of the U.S. Bankruptcy Code, 11 U.S.C. § 101 et seq. The bankruptcy filing follows months of missed debt payments, closed dispensaries, and unsuccessful restructuring negotiations with senior lenders. According to court documents filed in the United States Bankruptcy Court for the District of Delaware, The Cannabist Company listed assets between $500 million and $1 billion and liabilities in the same range. The company's collapse affects approximately 4,000 employees and thousands of medical cannabis patients who relied on its dispensaries for consistent access to medicine. Industry analysts estimate that the bankruptcy could trigger a cascade of consolidation across the multi-state operator sector, with smaller regional players and distressed assets likely to be acquired at significant discounts by better-capitalized competitors or private equity firms.

Why This Matters

The Cannabist Company bankruptcy represents a watershed moment for the $30 billion U.S. cannabis industry, exposing fundamental structural flaws in the multi-state operator business model under federal prohibition. The collapse affects multiple critical stakeholder groups and raises systemic questions about the future of cannabis commerce in America. For patients, the immediate impact is access disruption. The Cannabist Company operated medical dispensaries in states including Florida, Maryland, Pennsylvania, and Virginia, serving an estimated 250,000 registered medical cannabis patients. Many of these patients rely on specific formulations, consistent cannabinoid ratios, and reliable supply chains to manage conditions including chronic pain, epilepsy, PTSD, and cancer-related symptoms. Dispensary closures force patients to find alternative sources, often requiring travel to distant locations or switching to unfamiliar products that may not provide equivalent therapeutic benefit. For investors, the bankruptcy crystallizes billions of dollars in losses. The Cannabist Company was publicly traded on the Canadian Securities Exchange under the ticker CBST, with institutional investors including pension funds, mutual funds, and retail shareholders holding significant positions. The company's stock price declined more than 95 percent from its 2021 peak before trading was halted. Bondholders face potential recovery rates below 30 cents on the dollar, according to preliminary estimates from restructuring advisors. The collapse follows similar distress at other major operators including MedMen, Acreage Holdings, and Harborside, creating a pattern of value destruction that has made institutional capital increasingly scarce for the sector. For employees, the bankruptcy means immediate job losses and uncertain futures. The Cannabist Company employed approximately 4,000 people across cultivation, processing, retail, and corporate functions. Bankruptcy proceedings typically result in workforce reductions of 30 to 50 percent as operations are rationalized. Cannabis industry workers face particular challenges in job transitions because federal prohibition creates barriers to unemployment benefits in some jurisdictions and because cannabis-specific skills do not always translate to other industries. For the broader industry, the bankruptcy validates long-standing warnings about the unsustainability of the multi-state operator model under current federal policy. Section 280E of the Internal Revenue Code, 26 U.S.C. § 280E, prohibits cannabis businesses from deducting ordinary business expenses, resulting in effective tax rates exceeding 70 percent in some cases. The inability to access traditional banking services forces cannabis operators to manage large cash volumes, increasing security costs and operational complexity. Federal prohibition also prevents cannabis businesses from filing for bankruptcy protection under Chapter 11, creating a legal paradox where The Cannabist Company's filing may face challenges to its validity.

Background and History

The Cannabist Company traces its origins to Columbia Care, founded in 2012 as one of the earliest multi-state operators to pursue a national footprint in the emerging legal cannabis market.

Early Formation and Columbia Care (2012-2021)

Columbia Care was established in 2012 by Nicholas Vita, a former investment banker, with the explicit strategy of building a vertically integrated cannabis company that could operate across multiple state markets. The company secured one of the first medical cannabis licenses in New York in 2014, positioning itself as a premium operator focused on medical patients and pharmaceutical-grade cultivation standards. Between 2014 and 2018, Columbia Care expanded aggressively through license applications and acquisitions, entering markets including Massachusetts, Ohio, Pennsylvania, California, and Florida. The company's growth strategy relied heavily on debt financing and sale-leaseback transactions. By 2018, Columbia Care had raised more than $200 million through private placements and began trading publicly on the Canadian Securities Exchange through a reverse takeover transaction. The company positioned itself as a leader in medical cannabis, emphasizing its relationships with healthcare providers and its focus on consistent, pharmaceutical-quality products. Between 2018 and 2021, Columbia Care completed more than 15 acquisitions, including The Green Solution in Colorado, Project Cannabis in California, and gLeaf Medical in Pennsylvania and Virginia. The acquisition spree was fueled by cheap capital as Canadian and U.S. investors poured billions into the cannabis sector in anticipation of federal legalization. Columbia Care's enterprise value peaked above $2 billion in early 2021.

The Cresco Labs Merger and Cannabist Rebrand (2021-2023)

In March 2021, Columbia Care announced a definitive merger agreement with Cresco Labs, another major multi-state operator, in a transaction valued at approximately $2 billion. The proposed merger would have created the largest cannabis company in the United States by revenue, with operations in 18 states and projected annual revenue exceeding $1.4 billion. However, the merger faced immediate regulatory challenges. The Federal Trade Commission and state regulators in Illinois, Massachusetts, and New York raised antitrust concerns about market concentration, particularly in states where the combined entity would control more than 30 percent of retail licenses. The companies spent more than 18 months attempting to address regulatory concerns through proposed divestitures, but ultimately the merger was terminated in January 2023. The failed merger left Columbia Care in a weakened position. The company had incurred more than $25 million in transaction-related expenses and had delayed strategic initiatives while pursuing the Cresco combination. In March 2023, Columbia Care rebranded as The Cannabist Company, launching a new retail concept focused on education, product curation, and customer experience. The rebrand was accompanied by a strategic review and the announcement of $50 million in cost reductions.

Deteriorating Market Conditions (2023-2025)

The period from 2023 to 2025 saw catastrophic deterioration in cannabis market fundamentals. Wholesale cannabis prices collapsed as cultivation capacity far exceeded demand in mature markets. In California, wholesale flower prices declined from an average of $1,200 per pound in 2020 to below $400 per pound by 2024. In Michigan, wholesale prices fell below $800 per pound. In Colorado, some cultivators reported wholesale prices below $500 per pound for premium flower. The price collapse was driven by oversupply resulting from unlimited cultivation licenses in some states, improved cultivation efficiency, and the proliferation of home growing. The Cannabist Company's vertically integrated model, which had been promoted as a competitive advantage, became a liability as the company was forced to operate money-losing cultivation facilities to supply its retail dispensaries. Simultaneously, The Cannabist Company faced mounting debt obligations. The company had more than $400 million in senior secured debt with covenants requiring minimum EBITDA thresholds and restrictions on additional borrowing. As operating performance deteriorated, the company violated debt covenants in the third quarter of 2024, triggering technical default provisions. The company negotiated forbearance agreements with lenders but was unable to achieve the operational improvements necessary to cure the defaults. In late 2024, The Cannabist Company announced the closure of 25 underperforming dispensaries and the consolidation of cultivation operations in several states. The company also initiated discussions with restructuring advisors and attempted to raise rescue capital through a proposed $100 million equity offering, but the offering failed to attract sufficient investor interest.

Final Collapse and Bankruptcy Filing (2025-2026)

By early 2025, The Cannabist Company was in active restructuring negotiations with its senior lenders. The company retained Moelis & Company as financial advisor and Paul, Weiss, Rifkind, Wharton & Garrison as legal counsel. Lenders were represented by PJT Partners and Davis Polk & Wardwell. The parties explored multiple restructuring alternatives including debt-for-equity swaps, asset sales, and operational joint ventures. In the first quarter of 2026, negotiations broke down over disagreements about enterprise valuation and the treatment of junior creditors. Senior lenders argued that the company's enterprise value had declined to approximately $300 million, well below the face value of senior debt. Equity holders and junior creditors disputed this valuation and opposed restructuring proposals that would have eliminated their recovery. On May 18, 2026, The Cannabist Company filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the District of Delaware. The filing listed assets between $500 million and $1 billion and liabilities in the same range. The company announced its intention to pursue a sale of substantially all assets through a Section 363 auction process under 11 U.S.C. § 363, with stalking horse bids expected from strategic buyers and private equity firms.

Key Players

The Cannabist Company

The Cannabist Company operated as a vertically integrated multi-state operator with licenses in 19 states. The company's operations included approximately 130 retail dispensaries operating under The Cannabist, Columbia Care, and regional brand names; 30 cultivation facilities totaling more than 1.5 million square feet of canopy; and 15 processing and manufacturing facilities producing vaporizers, edibles, tinctures, and topicals. The company employed approximately 4,000 people and reported revenue of approximately $500 million in 2025, down from a peak of $625 million in 2022.

Senior Lenders

The Cannabist Company's senior secured lenders hold approximately $400 million in first-lien debt secured by substantially all company assets. The lending syndicate is led by Chicago Atlantic Real Estate Finance and includes several cannabis-focused debt funds. These lenders have the strongest position in the bankruptcy and are expected to drive the restructuring process, potentially converting debt to equity ownership of the reorganized company or supporting a sale process that maximizes their recovery.

Equity Holders and Junior Creditors

Public shareholders who purchased The Cannabist Company stock on the Canadian Securities Exchange face near-total losses. The company's stock traded above $7 per share in 2021 but declined to below $0.10 per share before trading was halted. Junior creditors including unsecured bondholders, trade vendors, and landlords hold claims totaling more than $200 million and face recovery rates likely below 20 cents on the dollar.

State Regulators

Cannabis Control Boards in 19 states have jurisdiction over The Cannabist Company's licenses and must approve any transfer of ownership through the bankruptcy process. Key regulatory agencies include the Florida Department of Health Office of Medical Marijuana Use, the Pennsylvania Department of Health Medical Marijuana Program, the Maryland Cannabis Administration, the Virginia Cannabis Control Authority, and the Ohio Division of Cannabis Control. These agencies face difficult decisions about whether to allow license transfers to new owners or to revoke licenses based on the bankruptcy filing.

Competing Multi-State Operators

The Cannabist Company's bankruptcy creates acquisition opportunities for better-capitalized competitors. Potential buyers include Curaleaf Holdings, Green Thumb Industries, Trulieve Cannabis, Verano Holdings, and Cresco Labs. These companies have stronger balance sheets and may seek to acquire The Cannabist Company's licenses and operating assets at distressed valuations. Private equity firms including Poseidon Asset Management, Tuatara Capital, and Merida Capital Partners have also expressed interest in cannabis distressed debt and may participate in the restructuring.

Legal and Regulatory Framework

The Cannabist Company bankruptcy occurs in a complex legal environment where federal prohibition creates unique challenges for restructuring cannabis businesses under U.S. bankruptcy law.

Federal Prohibition and the Controlled Substances Act

Cannabis remains a Schedule I controlled substance under the Controlled Substances Act, 21 U.S.C. § 812. Schedule I classification means cannabis is deemed to have no accepted medical use and a high potential for abuse. Federal prohibition creates the foundational legal conflict: cannabis businesses are violating federal law even when operating in compliance with state regulations. This conflict extends to bankruptcy proceedings. Section 362 of the Bankruptcy Code, 11 U.S.C. § 362, provides for an automatic stay that prevents creditors from taking collection actions against a debtor. However, several bankruptcy courts have held that cannabis businesses cannot access bankruptcy protection because doing so would require the court to facilitate ongoing violations of the Controlled Substances Act. Notable cases include In re Arenas, 535 B.R. 845 (10th Cir. BAP 2015), where the Bankruptcy Appellate Panel held that a cannabis business could not proceed in bankruptcy because the debtor's ongoing operations violated federal law. The Cannabist Company's bankruptcy filing directly challenges this precedent. The company's legal team is expected to argue that recent developments including the Cole Memorandum (rescinded but reflecting DOJ enforcement priorities), the Rohrabacher-Farr Amendment (now the Joyce-Leahy Amendment) prohibiting DOJ from interfering with state medical cannabis programs, and the pending DEA rescheduling process create a changed legal landscape that permits bankruptcy proceedings for state-compliant cannabis operators.

Section 280E and Tax Treatment

Internal Revenue Code Section 280E, 26 U.S.C. § 280E, prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. The provision was enacted in 1982 in response to a Tax Court decision allowing a cocaine dealer to deduct business expenses. Section 280E has been applied to state-legal cannabis businesses since the IRS issued guidance in the 1990s. The impact of Section 280E on cannabis operators is severe. While businesses can deduct cost of goods sold under Treasury Regulation 1.471, they cannot deduct rent, salaries for non-production employees, marketing, professional fees, or other ordinary expenses. This results in effective tax rates of 60 to 80 percent of gross profit, compared to 25 to 35 percent for comparable businesses in other industries. Section 280E contributed directly to The Cannabist Company's financial distress. The company's tax burden exceeded $100 million annually despite operating losses on a GAAP basis. This cash drain prevented the company from investing in operational improvements, paying down debt, or building reserves to weather market downturns.

Banking and Financial Services Restrictions

Federal prohibition prevents most banks from serving cannabis businesses due to anti-money laundering provisions of the Bank Secrecy Act, 31 U.S.C. § 5311 et seq., and guidance from the Financial Crimes Enforcement Network (FinCEN). While FinCEN issued guidance in 2014 outlining how banks could serve cannabis businesses while managing compliance risk, most major banks have declined to serve the sector due to reputational concerns and regulatory uncertainty. The lack of banking access forced The Cannabist Company to operate largely in cash, increasing security costs, limiting payment options for customers, and creating operational inefficiencies. The company maintained limited banking relationships with small credit unions and cannabis-focused financial service providers, but these relationships were expensive and offered limited services compared to traditional commercial banking. The SAFE Banking Act, which would protect banks serving state-legal cannabis businesses from federal penalties, has passed the U.S. House of Representatives multiple times but has not been enacted into law. The absence of banking access contributed to The Cannabist Company's inability to manage its financial distress effectively.

State-by-State Breakdown

The Cannabist Company's bankruptcy affects operations across 19 states, each with distinct regulatory frameworks and different implications for license transfers and operational continuity.

Florida

Florida represents The Cannabist Company's largest market by revenue, with 28 dispensaries and two cultivation facilities. Florida operates a vertically integrated medical cannabis program under Florida Statutes § 381.986, with a limited number of licensed Medical Marijuana Treatment Centers. The Cannabist Company holds one of approximately 25 active licenses. The Florida Department of Health Office of Medical Marijuana Use must approve any license transfer. Florida law requires background checks and financial disclosures for new license holders. The state has historically been protective of existing license holders and may facilitate a transfer to preserve patient access.

Pennsylvania

Pennsylvania's medical marijuana program, established under the Medical Marijuana Act, 35 P.S. § 10231.101 et seq., operates through a limited-license structure. The Cannabist Company operates 15 dispensaries and two cultivation facilities in Pennsylvania. The Pennsylvania Department of Health must approve license transfers, which require demonstration of financial stability and compliance history. Pennsylvania has been more restrictive than some states in approving license transfers, particularly for operators with compliance issues.

California

California's adult-use and medical cannabis markets operate under the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA). The Cannabist Company operates eight dispensaries in California, primarily in the San Francisco Bay Area and San Diego. California's Bureau of Cannabis Control (now the Department of Cannabis Control) has broad discretion over license transfers. California's oversaturated market and low wholesale prices make the state's assets among the least valuable in The Cannabist Company's portfolio.

Colorado

Colorado, the first state to implement adult-use cannabis sales in 2014, operates under the Colorado Marijuana Code. The Cannabist Company operates 12 dispensaries in Colorado through its acquisition of The Green Solution. The Colorado Marijuana Enforcement Division must approve ownership changes. Colorado has a mature regulatory framework and has generally facilitated license transfers that maintain operational continuity.

Massachusetts

Massachusetts legalized adult-use cannabis through a 2016 ballot initiative, with regulations codified at 935 CMR 500.000. The Cannabist Company operates six dispensaries in Massachusetts. The Massachusetts Cannabis Control Commission must approve license transfers and has been deliberate in its review process, often taking six to twelve months to approve ownership changes. The commission has prioritized social equity applicants in recent licensing rounds, which may influence its approach to approving transfers of The Cannabist Company's licenses.

Ohio

Ohio's medical marijuana program operates under Ohio Revised Code Chapter 3796. The Cannabist Company operates five dispensaries and one cultivation facility in Ohio. The Ohio Division of Cannabis Control must approve license transfers. Ohio voters approved adult-use legalization in 2023, with sales beginning in 2024, creating growth potential that may attract buyers for The Cannabist Company's Ohio assets.

New York

New York was one of The Cannabist Company's original markets, with the company receiving one of the first five medical cannabis licenses in 2014. The company operates four dispensaries in New York. New York's cannabis program has undergone significant changes, with adult-use legalization in 2021 and ongoing implementation of the Marijuana Regulation and Taxation Act. The New York Office of Cannabis Management must approve license transfers. New York has prioritized social equity applicants and may scrutinize transfers to large multi-state operators.

Other States

The Cannabist Company also operates in Arizona, Delaware, Illinois, Maryland, Michigan, Missouri, New Jersey, South Dakota, Utah, Virginia, Washington D.C., and West Virginia. Each jurisdiction has distinct regulatory requirements for license transfers, with approval timelines ranging from 60 days to more than one year. The company's licenses in emerging markets including Virginia and West Virginia may be particularly attractive to buyers due to limited competition and growth potential.

Market and Business Implications

The Cannabist Company bankruptcy accelerates consolidation trends in the multi-state operator sector and forces a reckoning with the fundamental economics of cannabis commerce under federal prohibition. The immediate market impact is a repricing of cannabis assets. The Cannabist Company's bankruptcy filing will establish valuation benchmarks through the Section 363 auction process. Early indications suggest that dispensary licenses may trade at 30 to 50 percent discounts to pre-bankruptcy valuations, with cultivation assets facing even steeper discounts due to overcapacity. These valuations will influence merger and acquisition activity across the sector and may trigger impairment charges at other public cannabis companies. For wholesale markets, The Cannabist Company's bankruptcy may provide modest supply relief. The company's cultivation facilities produced an estimated 50,000 pounds of cannabis annually. If new owners rationalize cultivation operations or close unprofitable facilities, wholesale prices may stabilize in some markets. However, structural oversupply is likely to persist in California, Michigan, and Colorado regardless of The Cannabist Company's restructuring. The bankruptcy also highlights the advantages of single-state operators and smaller regional players. Companies focused on one or two states with lean cost structures and minimal debt have outperformed large multi-state operators over the past three years. Single-state operators avoid the complexity and overhead of multi-state compliance, benefit from deeper local market knowledge, and can optimize operations for specific regulatory environments. The Cannabist Company's collapse may accelerate a strategic shift away from the multi-state operator model toward focused regional strategies. For capital markets, the bankruptcy reinforces the risk premium on cannabis investments. Institutional investors who suffered losses on The Cannabist Company and other distressed operators will demand higher returns and stronger governance protections for future investments. Equity capital is likely to remain scarce, forcing cannabis companies to rely on expensive debt financing from specialized cannabis lenders. The cost of capital disadvantage relative to other industries will persist until federal reform provides access to traditional banking and capital markets. Private equity firms and distressed debt investors view The Cannabist Company's bankruptcy as an opportunity. Firms including Poseidon Asset Management, Tuatara Capital, Chicago Atlantic, and Silver Spike Capital have raised funds specifically to invest in distressed cannabis assets. These investors can acquire licenses and operating assets at significant discounts and may consolidate acquisitions into new platforms. The involvement of sophisticated financial investors may professionalize cannabis operations and improve capital allocation discipline across the sector.

What Experts Say

Industry analysts, restructuring professionals, and policy advocates have offered varied perspectives on the causes and implications of The Cannabist Company's bankruptcy. According to cannabis industry analyst Matt Karnes of GreenWave Advisors, the bankruptcy was inevitable given the company's debt load and deteriorating market conditions. Karnes noted that The Cannabist Company's enterprise value had declined by more than 80 percent since 2021, making it impossible to service debt obligations. He emphasized that similar distress is likely at other highly leveraged multi-state operators. Emily Paxhia, co-founder of Poseidon Asset Management, a cannabis-focused investment firm, described the bankruptcy as a symptom of federal policy failure. According to Paxhia, Section 280E and banking restrictions create insurmountable structural disadvantages that prevent cannabis businesses from competing on equal footing with other industries. She argued that federal reform is essential to prevent additional bankruptcies and enable the cannabis industry to mature into a stable sector. Restructuring attorney Elliot Moskowitz of Schulte Roth & Zabel, who has represented cannabis companies in distressed situations, noted that the legal uncertainty around cannabis bankruptcies complicates the restructuring process. Moskowitz explained that bankruptcy courts have discretion to dismiss cases involving ongoing violations of federal law, creating risk for all parties. He suggested that The Cannabist Company's case may establish important precedent about whether state-compliant cannabis operators can access bankruptcy protection. Morgan Fox, political director of the National Organization for the Reform of Marijuana Laws (NORML), emphasized the patient impact of The Cannabist Company's bankruptcy. According to Fox, dispensary closures force medical cannabis patients to find alternative sources, often at higher cost and with less product consistency. He argued that the bankruptcy demonstrates the urgent need for federal legalization to stabilize the cannabis industry and protect patient access. Andrew Kline, a cannabis attorney and former federal prosecutor, offered a different perspective, arguing that The Cannabist Company's bankruptcy reflects poor management decisions rather than solely federal policy constraints. According to Kline, the company pursued unsustainable growth through debt-financed acquisitions and failed to adapt its strategy when market conditions changed. He noted that some multi-state operators with more conservative growth strategies and stronger balance sheets have remained profitable despite the same federal policy environment.

What's Next

The Cannabist Company bankruptcy will unfold over 12 to 24 months through a structured court process that will determine the fate of the company's assets and establish precedent for future cannabis restructurings. The immediate next step is the first-day hearing in the United States Bankruptcy Court for the District of Delaware, where the company will seek approval of debtor-in-possession financing to fund operations during the bankruptcy process. The company has negotiated a $50 million DIP facility with its senior lenders, which will provide liquidity to maintain dispensary operations and preserve asset value. The court will also consider motions to approve employee retention programs, maintain customer programs, and pay critical vendors. Within 60 days of the bankruptcy filing, The Cannabist Company is expected to file a motion seeking approval of bidding procedures for a Section 363 sale of substantially all assets. The company has indicated it will pursue a sale process rather than a traditional plan of reorganization. A stalking horse bidder will likely emerge, establishing a floor valuation and providing certainty of execution. Competing bids will be due approximately 30 days after bidding procedures are approved, with an auction held shortly thereafter. The auction process will test market appetite for distressed cannabis assets. Potential buyers include Curaleaf Holdings, Green Thumb Industries, Trulieve Cannabis, Verano Holdings, and private equity firms. The auction may result in a single buyer acquiring substantially all assets, or the company may be broken up with different buyers acquiring state-by-state operations. License transfer approvals from state regulators will be a critical path item, potentially extending the timeline by six to twelve months. Simultaneously, the bankruptcy will test the legal question of whether cannabis businesses can access Chapter 11 protection. The U.S. Trustee or creditors may file motions to dismiss the case based on ongoing violations of the Controlled Substances Act. The Cannabist Company's legal team will argue that state-compliant cannabis operations should be permitted to reorganize under bankruptcy law, particularly given recent developments in federal enforcement policy and the pending DEA rescheduling process. The court's ruling on this issue will have implications for the entire cannabis industry. For creditors, the bankruptcy will establish recovery rates that inform valuations across the cannabis debt market. Senior secured lenders are expected to recover 60 to 80 cents on the dollar, while unsecured creditors may recover 10 to 20 cents on the dollar. Equity holders will likely receive no recovery. These outcomes will influence pricing for cannabis debt securities and may trigger mark-to-market losses at other cannabis lenders. The broader industry will watch for contagion effects. Several other multi-state operators face similar financial stress, including high debt loads, covenant violations, and deteriorating operating performance. If The Cannabist Company's bankruptcy triggers a loss of confidence among lenders or leads to tightened credit conditions, additional bankruptcies may follow. Conversely, if the bankruptcy process results in successful license transfers and operational continuity, it may provide a roadmap for other distressed operators to restructure their balance sheets. Federal policy developments will also influence the trajectory of The Cannabist Company's restructuring and the broader industry. The Drug Enforcement Administration is conducting a review of cannabis scheduling under the Controlled Substances Act, with the possibility of rescheduling cannabis to Schedule III. Rescheduling would eliminate Section 280E tax penalties and potentially facilitate banking access, dramatically improving the economics of cannabis operations. However, the rescheduling process is expected to take at least 18 to 24 months, likely too late to benefit The Cannabist Company's bankruptcy but potentially stabilizing the industry for other operators. Legislative developments including the SAFE Banking Act and comprehensive cannabis reform bills remain possible but face uncertain prospects in Congress. The Cannabist Company's bankruptcy may serve as a catalyst for renewed legislative attention to the structural challenges facing state-legal cannabis businesses.

Further Reading

• United States Bankruptcy Court for the District of Delaware case docket for In re The Cannabist Company Holdings, Inc. (case number to be assigned upon filing) — https://www.deb.uscourts.gov/
• Internal Revenue Code Section 280E, 26 U.S.C. § 280E — https://www.law.cornell.edu/uscode/text/26/280E
• Controlled Substances Act, 21 U.S.C. § 812 — https://www.law.cornell.edu/uscode/text/21/812
• U.S. Bankruptcy Code, 11 U.S.C. § 101 et seq. — https://www.law.cornell.edu/uscode/text/11
• In re Arenas, 535 B.R. 845 (10th Cir. BAP 2015) — Bankruptcy Appellate Panel decision on cannabis business bankruptcy eligibility
• Financial Crimes Enforcement Network (FinCEN) Guidance on Marijuana-Related Businesses, FIN-2014-G001 (February 14, 2014) — https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses
• Florida Statutes § 381.986 — Florida medical marijuana law — https://www.flsenate.gov/Laws/Statutes/2023/381.986
• Pennsylvania Medical Marijuana Act, 35 P.S. § 10231.101 et seq. — https://www.legis.state.pa.us/cfdocs/legis/li/uconsCheck.cfm?yr=2016&sessInd=0&act=16
• Ohio Revised Code Chapter 3796 — Ohio medical marijuana law — https://codes.ohio.gov/ohio-revised-code/chapter-3796
• GreenWave Advisors cannabis industry research and analysis — https://www.greenwaveadvisors.com/
• National Organization for the Reform of Marijuana Laws (NORML) — https://norml.org/
• Marijuana Policy Project federal and state cannabis policy tracking — https://www.mpp.org/